Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ambit completes $60.5mm IPO

Executive Summary

Ambit Biosciences Corp. (developing kinase inhibitors) has finally completed its initial public offering, netting $60.5mm through the sale of 8mm shares at $8. The company first filed in November 2010 but withdrew in June 2011, and then filed again in February 2013. Earlier this month, Ambit announced that it hoped to sell 4.6mm shares for between $13-15 apiece.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies